ABSTRACT
Alpha-galactosyl ceramide (α-GalCer) has been known to bind to the CD1d receptor on dendritic cells and activate invariant natural killer T (iNKT) cells, which subsequently secrete T-helper-cell 1 (Th1) and Th2 cytokines, which correlate with anti-infection activity and the prevention of autoimmune diseases, respectively. α-GalCer elicits the secretion of these two cytokines nonselectively, and thus, its effectiveness is limited by the opposing effects of the Th1 and Th2 cytokines. Reported here is the synthesis of a new α-GalCer analog (compound C34), based on the structure of CD1d, with a 4-(4-fluorophenoxy) phenyl undecanoyl modification of the
N
-acyl moiety of α-GalCer. Using several murine bacterial and viral infection models, we demonstrated that C34 has superior antibacterial and antiviral activities in comparison with those of several other Th1-selective glycolipids and that it is most effective by administering it to mice in a prophylactic manner before or shortly after infection.
摘要
众所周知,α-半乳糖神经酰胺(α-GalCer)能与树突状细胞上的 CD1d 受体结合,并激活不变自然杀伤 T 细胞(iNKT),这些细胞随后会分泌 T 辅助细胞 1(Th1)和 Th2 细胞因子,它们分别与抗感染活性和预防自身免疫性疾病有关。α-GalCer 可非选择性地诱导这两种细胞因子的分泌,因此其有效性受到 Th1 和 Th2 细胞因子对立效应的限制。本文以 CD1d 的结构为基础,合成了一种新的α-GalCer 类似物(化合物 C34)。
N
α-GalCer的N-酰基修饰。我们利用几种小鼠细菌和病毒感染模型证明,与其他几种 Th1 选择性糖脂相比,C34 具有更优越的抗菌和抗病毒活性,而且在感染前或感染后不久以预防性方式给小鼠服用 C34 效果最好。